Concepedia

Author

Kristen Sweet

Janssen (United States)

Also Known As

K Sweet, K. Sweet, Kristen M. Sweet, Kristen Sweet

29

Publications

637

Citations

10

H-Index

15

Concepts

All Affiliations

Janssen (United States)Janssen Scientific Affairs (United States)University of GlasgowDrexel UniversityUniversity of California, San Francisco
KS

About

Kristen Sweet is an author at Janssen (United States) specializing in autoimmune disease, rheumatoid arthritis, and rheumatology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

119

2

Pathology

2

2

119

3

Rheumatology

2

2

119

4

Immunology

1

1

25

5

Orthopaedics

1

1

94

Kristen Sweet

×

10

Publications

609

Citations

10

H-Index

YearCitations

Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

Atul Deodhar, Lianne S. Gensler, Joachim Sieper,

Arthritis & Rheumatology

2018

311

Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies

Philip J. Mease, Philip Helliwell, Dafna D. Gladman,

The Lancet Rheumatology

2021

94

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials

Philip Helliwell, Dafna D. Gladman, Soumya D. Chakravarty,

RMD Open

2020

57

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

Kristen Sweet, Qingxuan Song, Matthew J. Loza,

RMD Open

2021

36

Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus

Matteo Cesaroni, Loqmane Seridi, Matthew J. Loza,

Arthritis & Rheumatology

2020

25

Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)

Georg Schett, Matthew J. Loza, Arumugam Palanichamy,

Rheumatology and Therapy

2022

25

Responsiveness of Serum C‐Reactive Protein, Interleukin‐17A, and Interleukin‐17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double‐Blind, Placebo‐Controlled Trials

Stefan Siebert, Kristen Sweet, B. Dasgupta,

Arthritis & Rheumatology

2019

21

Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials

Arthur Kavanaugh, Xenofon Baraliakos, Sheng Gao,

Advances in Therapy

2023

15

Gluten-induced Neurocognitive Impairment

Jessica B. Edwards George, Babatunde Aideyan, Kayla Yates,

Journal of Clinical Gastroenterology

2021

14

THU0052 USTEKINUMAB AND GUSELKUMAB TREATMENT RESULTS IN DIFFERENCES IN SERUM IL17A, IL17F AND CRP LEVELS IN PSORIATIC ARTHRITIS PATIENTS: A COMPARISON FROM USTEKINUMAB PH3 AND GUSELKUMAB PH2 PROGRAMS

Stefan Siebert, Matthew J. Loza, Qingxuan Song,

Annals of the Rheumatic Diseases

2019

11

Page 1